A vision and mission to transform women’s health

From discovery to innovation

Founded in 2020, AOA Dx was created to ensure that women have access to the most innovative early detection platform in their fight against cancer. More than 90% of new discoveries in medical innovation stay in research within an academic setting and are never commercialized and widely adopted to help patients. We’re here to change that.

Vision

Create a world where more women
are living longer healthier lives

Mission

Transform women’s health

AOA Dx History

June 2020
AOA Dx founded
AOA Dx was founded by 3 entrepreneurs after working together for over 10 years within the women’s health industry
June 2020
May 2021
$2.5 million Pre-Seed raised
Led by Joyance Partners, the round included notable investments from Avestria Ventures, AlleyCorp, Launchpad Venture Group, TBD Angels and Kyto Technology and Life Science, among others
May 2021
August 2021
First proof of concept study completed
Analyzed 500 retrospective samples reflective of intended use population in ovarian cancer
August 2021
August 2021
AOA Dx Scientific Collaboration Partner awarded $650,000 grant by the Canadian Institute of Health Research
AOA Dx’s scientific collaboration partner, Professor Uri Saragovi of McGill University, was awarded a $650,000 CAD grant for further development of AKRIVIS GD™
August 2021
March 2022
$5 million Seed round raised
Led by Avestria Ventures with funds from Y Combinator, AlleyCorp, The Helm, RH Capital, Olive Tree Capital and other notable investors, the round gives AOA Dx the ability to develop the the AKRIVIS GD™ assay and expand their full-time team
March 2022
July 2022
Doubled the AOA Dx team
Expanded the AOA Dx team from 3 founders to a total of 6 employees across development, clinical, and operations departments
July 2022
September 2022
Platform feasibility assessed
Liquid chromatography-mass spectrometry (LC-MS) technology results support the development of liquid biopsy platform for multiple cancer indications for the detection of Tumor Marker Gangliosides in serum
September 2022
December 2022
OVERT study kicked off
First patient enrolled in the OVERT prospective study
December 2022
March 2023
Peer reviewed manuscript published in frontiers oncology
“GD2 and GD3 gangliosides as diagnostic biomarkers for all stages and subtypes of epithelial ovarian cancer” is published, highlighting the power of biomarkers GD2 and GD2 as an ovarian cancer diagnostic
March 2023
April 2023
Dr. Kevin Elias selected as Principal Investigator for the OVERT clinical study
A top Key Opinion Leader in ovarian cancer, Dr. Elias, Director of Gynecologic Oncology Laboratory at Brigham and Women's Hospital and Assistant Professor of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School, is selected as a leading physician and study coordinator
April 2023
July 2023
$17.2 million financing round closed
Led by Good Growth Capital with participation from strategic diagnostic investor Labcorp Venture Fund and other leading investors including RH Capital, Y Combinator, Astia Fund and Adaptive Capital Partners, the funding allows AOA Dx to open new lab facilities, expand the OVERT study, and further develop the GlycoLocate™ platform
July 2023
September 2023
Doubled the AOA Dx team again
AOA Dx grows to 12 full-time employees, growing their development and clinical teams
September 2023
October 2023
Glycocode review paper published in Frontiers Oncology
“The cancer glycocade as a family of diagnostic biomarkers, exemplified by tumor-associated gangliosides” is published, highlighting the power of tumor-marker gangliosides to detect cancer, even at the earliest stages
October 2023
January 2024
AOA Dx opened lab facilities in Denver, CO
AOA Dx opens their first headquarter lab, providing the team with space and equipment to complete in-house research and development
January 2024

Awards and Accelerators

Legal

Copyright 2020 – 2024

Privacy Policy

Contact

info@aoadx.com

press@aoadx.com

careers@aoadx.com

6860 Broadway, Denver CO 80221

Follow
Instagram Linkedin Twitter

Website by Sungraphic